Navigation Links
Antibody extends life of mice with breast cancer

A monoclonal antibody developed by researchers at the University at Buffalo has been shown to extend significantly the survival of mice with human breast-cancer tumors and to inhibit the cancer's spread to the lungs in the animals by more than 50 percent.

The antibody, named JAA-F11, targets a particular disaccharide, an antigen known as TF-Ag, which aids the adhesion and spread of certain cancer cells. While the antibody did not kill the cancer cells, it blocked stages of cancer-cell growth that allow the cells to adhere to organ tissue, the research showed.

Results of the research appeared in the November 2006 issue of the journal Neoplasia.

Mice with breast-cancer tumors that received the antibody had a median survival time of 72 days, compared to 57 days for the animals that did not receive JAA-F11, the study found. In addition, exposing cultures of tumor cells to the antibody inhibited cell growth by a statistically significant 16 percent.

Kate Rittenhouse-Olson, Ph.D., associate professor of clinical and laboratory sciences in the UB School of Medicine and Biomedical Sciences, is senior author on the study.

"This antibody binds with a carbohydrate on the tumor cell surface that is involved in adhesion of the cell during the metastatic process," said Rittenhouse-Olson. "Not only would drugs attached to the antibody JAA-F11 bind to the tumor cell surface to direct their cytotoxic effect, but the binding of the antibody itself would block the cell from metastasizing."

The antibody was tested using in vitro models of tumor cell growth, in assays to determine its ability to damage or kill cells (cytotoxicity), in various models of cancer metastasis, and, finally, in mice with metastatic breast cancer.

"In addition to providing a survival advantage," said Rittenhouse-Olson, "JAA-F11 immunotherapy reduced the metastatic tumor burden significantly, reflected by both a dramatic decline in the overall
'"/>

Source:University at Buffalo


Page: 1 2

Related biology news :

1. Antibody signal may redirect inflammation to fuel cancer
2. Antibody therapy prevents type 1 diabetes in mice
3. Combined treatment extends life expectancy for lung cancer patients
4. Single molecule extends fat mice lives by reversing gene pathways associated with disease in obese
5. Viral DNA sequence a possible trigger for breast cancer
6. Used in a new way, RNA interference permanently silences key breast cancer gene
7. Biomarkers isolated from saliva successfully predict oral and breast cancer
8. Study reveals dramatic difference between breast cancers in US and Africa
9. Compounds in plastic packaging act as environmental estrogens altering breast genes
10. Alcohol consumption disrupts breastfeeding hormones
11. VCU Massey Cancer Center study shows enzyme linked to spread of breast cancer cells
Post Your Comments:
Breaking Biology News(10 mins):Study finds new relationship between gene duplication and alternative splicing in plants 2Study finds new relationship between gene duplication and alternative splicing in plants 3IgeaCare Solutions Inc. Emerges Under New Leadership and Funding 2New York autopsies show 2009 H1N1 influenza virus damages entire airway 2New York autopsies show 2009 H1N1 influenza virus damages entire airway 3Reportlinker Adds 2008 2009 Healthcare Research Review Report 56185 1Reportlinker Adds 2008 2009 Healthcare Research Review Report 56185 2Reportlinker Adds 2008 2009 Healthcare Research Review Report 56185 3Reportlinker Adds 2008 2009 Healthcare Research Review Report 56185 4Reportlinker Adds 2008 2009 Healthcare Research Review Report 56185 5Reportlinker Adds 2008 2009 Healthcare Research Review Report 56185 6Reportlinker Adds 2008 2009 Healthcare Research Review Report 56185 7Reportlinker Adds 2008 2009 Healthcare Research Review Report 56185 8Reportlinker Adds 2008 2009 Healthcare Research Review Report 56185 9Reportlinker Adds 2008 2009 Healthcare Research Review Report 56185 10Reportlinker Adds 2008 2009 Healthcare Research Review Report 56185 11Reportlinker Adds 2008 2009 Healthcare Research Review Report 56185 12Reportlinker Adds Pediatric Health Care Products and Services Report 56182 1Reportlinker Adds Pediatric Health Care Products and Services Report 56182 2Reportlinker Adds Pediatric Health Care Products and Services Report 56182 3Reportlinker Adds Pediatric Health Care Products and Services Report 56182 4Reportlinker Adds Smart Glass 3A Technologies and Global Markets Report 13840 1Reportlinker Adds Smart Glass 3A Technologies and Global Markets Report 13840 2Reportlinker Adds Smart Glass 3A Technologies and Global Markets Report 13840 3
Breaking Biology Technology:Dip ordinary paper into ink infused with nanotubes and nanowires to create an instant battery 2Myriant Technologies LLC Selected for $50 Million Award for Succinic Acid Biorefinery Project 2Enerkem Awarded $50 Million Funding by U.S. Department of Energy for its Mississippi Biorefinery Project 2Enerkem Awarded $50 Million Funding by U.S. Department of Energy for its Mississippi Biorefinery Project 3AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 2AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 3AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 4AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 5AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 6